Please assess the completion status of the following clinical trial:

Trial Title: Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Subject:~Inclusion criteria~* Must be waitlisted for a kidney transplant (dialysis is not a requirement if a patient is waitlisted)~* Listed for an isolated kidney transplant with ≤2555 days of accrued transplant waiting time and/or ≤2555 days of dialysis time for blood group A, B, or O, by enrollment~* Listed for an isolated kidney transplant with ≤1825 days of accrued transplant waiting time and/or ≤1825 days of dialysis time for blood group AB, by enrollment~* No available living kidney donor~* Between 30-70 years of age, by enrollment~* Have a panel reactive antibody level ≤97%~* eGFR \<15ml/min/1.73m2 as calculated using the 4 variable MDRD equation~* Obtained agreement for participation from the patient's treating transplant nephrologist~* Able to travel to the University of Pennsylvania for routine post-transplant visits and study visits for a minimum of 6 months after transplantation~* No active illicit substance abuse~* Weigh at least 50kg~* Women must agree to use birth control in accordance with Mycophenolate Risk Evaluation and Mitigation Strategy (REMS) following transplant due to the increased risk of birth defects and/or miscarriage~* Both men and women must agree to use at least one barrier method to prevent any secretion exchange~* Inclusion criteria for treatment (not for entry as study patient) will include any detectable HCV RNA~* Able to provide informed consent~Exclusion criteria~* Hepatocellular carcinoma~* Patients with primary focal segmental glomerulosclerosis (FSGS), FSGS recurring after previous transplant, or disease process with increased risk of causing early graft failure as per the treating nephrologist~* HIV positive~* HCV RNA positive (can be isolated HCV antibody positive provided the subject has no history of previously treated HCV)~* Hepatitis B surface antigen positive~* Any other chronic liver disease (excluding non-alcoholic fatty liver disease (NAFLD) with abnormal liver enzymes~* Persistently elevated liver transaminases~* Significant hepatic fibrosis on screening elastography (≥f2 fibrosis)~* Pregnant or nursing (lactating) women~* Known allergy or intolerance to tacrolimus that would require post-transplant administration of cyclosporine, rather than tacrolimus given the drug-drug interaction between cyclosporine and Zepatier~* Waitlisted for a multi-organ transplant (e.g., pancreas-kidney, heart-kidney, etc.)~* Significant cardiomyopathy defined as either:~  * Left ventricular ejection fraction \<40% on most recent echocardiogram~ * Left ventricular ejection fraction ≥40% but \<50% on most recent echocardiogram with an \<5 METS of exercise tolerance~ * Reversible ischemia on stress testing without revascularization~Donor Organ Selection:~Inclusion Criteria~* Detectable HCV RNA~* Age ≤60 years~* Study modified Kidney donor profile index (KDPI) score ≤0.856 - calculated as if the kidney were HCV-negative (https://optn.transplant.hrsa.gov/resources/allocation-calculators/kdpi-calculator/)~Exclusion Criteria~* Anatomical issues in the kidney allograft that raise the risk of post-transplant complications (e.g., number or length of renal arteries or veins)~* Confirmed HIV positive~* Confirmed HBV positive (positive Hepatitis B surface antigen and/or HBV DNA)~* Known previously failed treatment for HCV using a regimen with a direct-acting antiviral (can have received interferon monotherapy and/or interferon + ribavirin combination therapy)

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Direct-acting antiviral treatment for HCV (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).